These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27601362)

  • 1. Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.
    Miaris N; Maltezou M; Papaxoinis G; Visvikis A; Samantas E
    Clin Genitourin Cancer; 2017 Feb; 15(1):e99-e103. PubMed ID: 27601362
    [No Abstract]   [Full Text] [Related]  

  • 2. Pazopanib-associated posterior reversible encephalopathy syndrome with intracerebral haemorrhage.
    Miller-Patterson C; Fehnel CR
    BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28416534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
    Tatsumichi T; Tanaka H; Okazaki T; Takahashi K; Suzuki K; Kawakita K; Houchi H; Kuroda Y; Kosaka S
    J Clin Pharm Ther; 2021 Feb; 46(1):223-226. PubMed ID: 33044009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
    Asaithambi G; Peters BR; Hurliman E; Moran BP; Khan AS; Taylor RA
    J Clin Pharm Ther; 2013 Apr; 38(2):175-6. PubMed ID: 23210935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible posterior leukoencephalopathy syndrome induced by pazopanib.
    Chelis L; Souftas V; Amarantidis K; Xenidis N; Chamalidou E; Dimopoulos P; Michailidis P; Christakidis E; Prassopoulos P; Kakolyris S
    BMC Cancer; 2012 Oct; 12():489. PubMed ID: 23088634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible posterior leukoencephalopathy syndrome induced by axitinib.
    Levy A; Benmoussa L; Ammari S; Albiges L; Escudier B
    Clin Genitourin Cancer; 2014 Feb; 12(1):e33-4. PubMed ID: 24135633
    [No Abstract]   [Full Text] [Related]  

  • 7. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
    Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M
    Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
    Jeon SY; Lee NR; Yim CY
    BMC Nephrol; 2019 Jan; 20(1):1. PubMed ID: 30606155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.
    Cirkel GA; Hamberg P; Sleijfer S; Loosveld OJL; Dercksen MW; Los M; Polee MB; van den Berkmortel F; Aarts MJ; Beerepoot LV; Groenewegen G; Lolkema MP; Tascilar M; Portielje JEA; Peters FPJ; Klümpen HJ; van der Noort V; Haanen JBAG; Voest EE;
    JAMA Oncol; 2017 Apr; 3(4):501-508. PubMed ID: 27918762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
    Verzoni E; Grassi P; Montone R; Galli G; Necchi A; Procopio G
    Tumori; 2015; 101(6):701-3. PubMed ID: 26108242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concise drug review: pazopanib and axitinib.
    van Geel RM; Beijnen JH; Schellens JH
    Oncologist; 2012; 17(8):1081-9. PubMed ID: 22733795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
    Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report.
    Abdallah AO; Vallurupalli S; Kunthur A
    J Oncol Pharm Pract; 2016 Jun; 22(3):561-5. PubMed ID: 25956420
    [No Abstract]   [Full Text] [Related]  

  • 14. Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab.
    Zhong YY; McLean L; Buckle A; Siva S; Tran B
    Can J Urol; 2020 Aug; 27(4):10339-10341. PubMed ID: 32861263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma.
    Ornstein MC; Wood L; Elson P; Allman K; Beach J; Martin A; Gilligan T; Garcia JA; Rini BI
    Clin Genitourin Cancer; 2017 Apr; 15(2):e275-e280. PubMed ID: 27625016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.
    Guida A; Albiges L; Derosa L; Loriot Y; Massard C; Fizazi K; Escudier B
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1081-e1088. PubMed ID: 28888866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
    J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
    Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
    Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panniculitis in a patient with metastatic renal cell carcinoma on a tyrosine kinase inhibitor.
    Nafissi NN; Karlin N; Pittelkow MR; Dicaudo DJ; Mangold AR
    Anticancer Drugs; 2021 Apr; 32(4):474-475. PubMed ID: 33290313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib induced unilateral posterior reversible encephalopathy syndrome.
    Arslan BM; Bajrami A; Demir E; Cabalar M; Yayla V
    Ideggyogy Sz; 2017 Mar; 70(3-4):140-144. PubMed ID: 29870619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.